Chemomab Therapeutics (CMMB)
(Delayed Data from NSDQ)
$0.97 USD
-0.03 (-3.00%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $0.98 +0.01 (1.03%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Fundamental Charts
About Market Cap
As of the previous market close, Chemomab Therapeutics Ltd. Sponsored ADR has a market cap of $18.86M, which represents its share price of $1.00 multiplied by its outstanding shares number of 18.86M. As a small-cap company, CMMB's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
CMMB 0.97 -0.03(-3.00%)
Will CMMB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CMMB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CMMB
KURA Stock Rises More Than 15% This Past Week: Here's Why
TPST Stock Up on EMA's Orphan Drug Tag for Liver Cancer Therapy
CMMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
MRK's ADC Drug Combo Shows Antitumor Activity in Lymphoma Study
NTLA Stock Down as Patient Faces Adverse Event in Gene Therapy Study
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer
Other News for CMMB
Chemomab Therapeutics management to meet with Maxim
CMMB: Upcoming Meeting Hosted by Maxim on August 7-8
Chemomab Therapeutics announces data from Phase 2 SPRING trial of nebokitug
Analysts Conflicted on These Healthcare Names: Pfizer (PFE) and Chemomab Therapeutics (CMMB)
CMMB Advances Toward Phase 3 with FDA Approval on Key Milestones | CMMB Stock News